Description du projet
Un kit de dosimétrie pour les victimes d’accidents nucléaires
Il existe actuellement un manque d’outils pour la biodosimétrie de l’irradiation pouvant être utilisés dans le cas d’accidents nucléaires où les personnes sont exposées à des niveaux de radiation potentiellement dangereux. De même, il n’existe pas de dispositifs pouvant être utilisés par des non-spécialistes sur le terrain pour obtenir des résultats immédiats dans les cas d’irradiation corporelle partielle (ICP). Le projet DosiKit, financé par l’UE, a développé un dispositif et un test rapide pouvant identifier et classifier les personnes irradiées sur le terrain à la suite d’accidents nucléaires. Le projet espère commercialiser ce produit en 2022 sur le marché européen après l’achèvement d’importantes études réglementaires et d’évaluation des risques.
Objectif
Acubens was founded in 2014, to develop and commercialize new game-changer medical diagnostic devices around NRBC emergency. Our team gathers young and experimented doctors, and seasoned business managers, uniting their competencies to develop nuclear/radiological/biological innovative transportable biodosimetry devices. Nuclear/radiological accident can expose individuals to radiation, with the need for fast triage of potentially exposed people requiring immediate medical care. There is today a lack of irradiation biodosimetry tools that can be used in the field, by non-specialist staff, giving immediate results and exposure cartography in case of Partial-Body irradiation (PBI).
To fulfil this critical unmet need for better initial crisis management, we invented the DosiKit device and fast test (45 minutes) to identify and classify irradiated individuals, directly in the field. This development was initiated in 2009 by the French Atomic Energy Commission within the European Commission program, BOOSTER (‘BiO-dOSimetric Tools for triagE to Responders’), and then continued by Acubens.
DosiKit technology is protected by 3 international patents and has reached TRL6 with a prototype validated in a large-scale exercise performed with the French army. Several collaborations are undergoing for biological validation with French research institute and hospitals.
Scientific and technical development was published in 3 scientific publications and many international oral communications. A strong contact has established with French, Germany, Israel, US and Singapore armies (LoI).
This DosiKit product will be on the market in 2022, starting in Europe and then extending worldwide. Forecasted sales revenue is 15 M€ in 2024.
The objectives of this phase 1 SME-Instrument are: (1) the final Biological and Technological validation of the device, (2) IP, FTO, Regulatory and risk assessment studies and (3) a market survey in Europe and USA to schedule our commercial actions.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
92160 Nanterre
France
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.